Patients who take a hormone-suppressing drug to treat prostate cancer may be at greater risk for dementia and Alzheimer's.<br />A JAMA Network study of more than 150,000 men found a link between the degenerative diseases and androgen deprivation therapy.<br />Researchers cautioned doctors to further consider the risks of ADT before giving it to their patients to treat prostate cancer.<br />According to Business Insider, the study says older men taking the treatment have a 20-percent higher chance of dementia. <br />
